XORTX Therapeutics Inc.
XRTX evidence brief
What we can confirm
- Market Cap:
- $4.2M
What it means
What to watch
Prepared research question
What matters most for XRTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XRTX
XORTX Therapeutics Inc. is a late clinical-stage biotechnology company developing therapies for diseases related to aberrant purine and uric acid metabolism, including gout, ADPKD, type 2 diabetic nephropathy, and acute kidney injury [sec · filed 2026-03-20].
Key risk: No revenue and no profitability
Market Cap
$4.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
XORTX Therapeutics Inc. is a late clinical-stage biotechnology company developing therapies for diseases related to aberrant purine and uric acid metabolism, including gout, ADPKD, type 2 diabetic nephropathy, and acute kidney injury [sec · filed 2026-03-20].
- XORTX is a late clinical-stage biotechnology company focused on diseases modulated by aberrant purine and uric acid metabolism, such as gout, ADPKD, T2DN, and AKI [sec · filed 2026-03-20].
- The company has not generated any revenue to date and may never be profitable, with all financial resources devoted to R&D [sec · filed 2026-03-20].
- XRx-008 program for ADPKD has received U.S. Orphan Drug Designation and is eligible for accelerated approval with a single Phase 3 trial [sec · filed 2025-05-12].
- In August 2025, the company closed a private placement of 156,849 units at US$0.73 per unit, raising US$114,500 [sec · filed 2026-03-20].
- The company believes peak net sales revenue for its oxypurinol product could exceed US$500 million per year [sec · filed 2026-03-20].
What works
- XORTX has obtained U.S. Orphan Drug Designation for its XRx-008 program for ADPKD, which may provide market exclusivity and development incentives [sec · filed 2025-05-12].
- The FDA has aligned on endpoints and Phase 3 trial elements, making XORLO™ eligible for accelerated approval, potentially shortening the path to market [sec · filed 2025-05-12].
- The company has in-house small molecule and formulations design expertise, which it believes provides a competitive advantage and scalable manufacturing [sec · filed 2025-05-12].
What to weigh
- XORTX has not generated any revenue to date and may never be profitable, with no guarantee of FDA approval for its product candidates [sec · filed 2026-03-20].
- The company is still in early stages of development and has not completed development of any products, with significant clinical and regulatory risks ahead [sec · filed 2026-03-20].
- There is no assurance that clinical trials will be successful; setbacks in advanced trials are common in the pharmaceutical industry and could materially affect the business [sec · filed 2026-03-20].
- The company's financial resources are limited, as evidenced by a small private placement of US$114,500 in August 2025, which may constrain development timelines [sec · filed 2026-03-20].
From the filings
Quoted directly from source documents.
XORTX has not generated any revenue and may never be profitable.
“We have not generated any revenue to date and may never be profitable.”
SEC filings · March 20, 2026
XRx-008 program for ADPKD is eligible for accelerated approval.
“ongoing discussions with the FDA have aligned our endpoints and other Phase 3 clinical trial elements to make XORLO TM the Company's proprietary oxypurinol formulation, eligible for accelerated approval.”
SEC filings · May 12, 2025
Peak net sales revenue for the oxypurinol product could exceed US$500 million per year.
“The Company believes that peak net sales revenue for this product could reach more than US$500 million per year.”
SEC filings · March 20, 2026
Risks & what to watch (4)›
Key risks
- No revenue and no profitability — XORTX has not generated any revenue to date and may never be profitable, with all resources devoted to R&D [sec · filed 2026-03-20].
- Clinical trial failure risk — There is no assurance that clinical trials will be successful; setbacks in advanced trials are common and could materially affect the business [sec · filed 2026-03-20].
- Limited financial resources — The company raised only US$114,500 in a private placement in August 2025, indicating constrained funding for development [sec · filed 2026-03-20].
- Regulatory approval uncertainty — There is no guarantee that the FDA will approve any of XORTX's proposed uric acid lowering agents or product candidates [sec · filed 2026-03-20].
What to watch
- Initiation and results of the Phase 3 registration trial for XRx-008 (ADPKD program) [sec · filed 2025-05-12].
- FDA discussions and NDA submission for the oxypurinol product via the 505(b)(2) pathway [sec · filed 2025-05-12].
- Company's ability to secure additional financing given limited recent capital raise [sec · filed 2026-03-20].
- Progress on the XRX-OXY-102 clinical trial and other pipeline programs [sec · filed 2026-03-20].
Sources: SEC filings · Generated September 26, 2026 · How we verify sources →
Run XORTX Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available XORTX Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$6K
| Holder | Shares | Value |
|---|---|---|
| kingsview wealth management, llc | 15,000 | $6K |
| clearstead advisors, llc | 277 | $92 |
| td waterhouse canada inc. | 47 | $19 |
Short Interest
as of May 22, 2026- % of float
- 5.3%
- Days to cover
- 0.0
- Shares short
- 79,644
- Daily short volume (Aug 28, 2026)
- 12.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XRTX short interestFrequently asked questions
What is the AI investment thesis for XORTX Therapeutics Inc.?
XORTX Therapeutics Inc. is a late clinical-stage biotechnology company developing therapies for diseases related to aberrant purine and uric acid metabolism, including gout, ADPKD, type 2 diabetic nephropathy, and acute kidney injury [sec · filed 2026-03-20].
Who is the CEO of XORTX Therapeutics Inc.?
Dr. Allen Warren Davidoff Ph.D. is the chief executive officer of XORTX Therapeutics Inc. (XRTX).
Where is XORTX Therapeutics Inc. headquartered?
XORTX Therapeutics Inc. (XRTX) is headquartered in Calgary, AB, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.